LncRNA与慢性肾脏病的研究进展  

Recent advances in LncRNAs and chronic kidney disease

作　　者：王伟达 李昭君 陈园园 陈晓光[1] 张森[1] WANG Wei-da;LI Zhao-jun;CHEN Yuan-yuan;CHEN Xiao-guang;ZHANG Sen(Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院北京协和医学院药物研究所

出　　处：《药学学报》2019年第11期1918-1925,共8页Acta Pharmaceutica Sinica

基　　金：十三五“重大新药创制”科技重大专项(2018ZX09711001)

摘　　要：长链非编码RNA(long noncoding RNA,LncRNA)是一类不具备或较少具备编码能力的转录本。近年来,这些曾被认为是基因转录组"噪音"的LncRNA受到了极大的关注,并正成为生物调节中潜在的重要参与者。LncRNA具有广泛的生物学功能,其异常表达与癌症、免疫疾病和代谢疾病等多种疾病相关。慢性肾脏病(chronic kidney disease,CKD)在全球不同地区的发病率为10%~15%,具有增长率高、不知晓率高的特点。主要有糖尿病肾病、膜性肾病以及各种免疫介导的肾小球疾病。现在已有不少研究证据表明,LncRNA与肾脏有着密切的联系,或许可成为新的治疗靶点或新的生物标志物来诊断疾病的发生发展。本文将对LncRNA的功能以及LncRNA与各种慢性肾脏疾病的现有研究做一总结,并展望了LncRNA在治疗CKD方面临床应用的前景。Long non-coding RNAs(LncRNAs),defined as transcripts which are hundreds of nucleotides with little or non-protein coding potential.Recently,LncRNAs have caught much more attentions,instead of considering as noises of genome transcripts,and indeed they have been found to play important roles associated with some biological processes,such as tumorigenesis,immunology dysfunction,metabolism adjustment,and so on.The incidence of chronic kidney disease(CKD)in different regions of the world is about 10%to 15%,with high growth rate and high unawareness,including the diabetic nephropathy,membranous nephropathy,etc.Previous publications also suggest that LncRNAs have a close relationship with the kidneys,and it may become new therapeutic targets or new biomarkers to diagnose diseases.In this review,we will summarize LncRNAs’functions with chronic kidney diseases,and discuss the prospects of the clinical applications of LncRNAs in the treatment of CKD treatment.

关 键 词：长链非编码RNA 糖尿病肾病 膜性肾病 狼疮性肾炎 IGA肾炎 慢性肾脏病 

分 类 号：R966[医药卫生—药理学]